Related Experiment Video
Updated: Jan 26, 2026

Comparing Eye-tracking Data of Children with High-functioning ASD, Comorbid ADHD, and of a Control Watching Social Videos
Published on: December 7, 2018
Comparative Overall Comorbidity Burden Among Patients With Hidradenitis Suppurativa
Sarah Reddy1, Andrew Strunk1, Amit Garg1
1Department of Dermatology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, New Hyde Park, New York.
Insights
Patients with hidradenitis suppurativa (HS) have a significantly higher comorbidity burden, as measured by the Charlson Comorbidity Index (CCI), compared to psoriasis patients and controls. Higher CCI scores in HS patients are linked to increased mortality risk.
Area of Science:
- Dermatology
- Epidemiology
- Public Health
Background:
- The comorbidity burden in hidradenitis suppurativa (HS) patients remains under-evaluated.
- Understanding comorbidities is crucial for comprehensive HS patient management.
Purpose of the Study:
- To assess and compare the standardized comorbidity burden in HS patients against psoriasis patients and a control group.
- To investigate the association between comorbidity burden and mortality in HS.
Main Methods:
- Cross-sectional analysis of electronic health records from October 2013 to October 2018.
- Inclusion of 5,306 HS patients, 14,037 psoriasis patients, and 1,733,810 controls.
- Primary outcome: mean Charlson Comorbidity Index (CCI) score; secondary outcome: 5-year mortality risk.
Main Results:
- Matched HS patients exhibited a higher mean CCI score (1.95) than psoriasis (1.47) and control (0.95) groups.
- 13.5% of HS patients had a CCI score of 5 or greater, associated with a nearly 5-fold increased risk of 5-year mortality.
- Chronic pulmonary disease and diabetes were the most frequent comorbidities in HS patients.
Conclusions:
- HS patients face a substantial comorbidity burden, exceeding that of psoriasis patients and controls.
- Elevated comorbidity burden in HS is linked to increased mortality, underscoring the need for routine screening.
- Multidisciplinary approaches and routine screening measures are recommended for HS management.
Importance:
The overall comorbidity burden among patients with hidradenitis suppurativa (HS) has not been systematically evaluated.
Objectives:
To investigate the standardized overall comorbidity burden among patients with HS and to compare it with the comorbidity burden in patients with psoriasis and a control group.
Design, Setting, And Participants:
A cross-sectional analysis was conducted of 5306 patients with HS, 14 037 patients with psoriasis, and 1 733 810 controls identified using electronic health records data from October 1, 2013, through October 1, 2018.
Main Outcome And Measure:
The primary outcome was the mean Charlson Comorbidity Index (CCI) score.
Results:
Each matched cohort had 3818 patients (2789 women and 1029 men; mean [SD] age, 45.7 [15.0]). Before matching, the overall mean (SD) CCI score was highest among the psoriasis cohort (2.33 [3.13]), followed by the HS cohort (1.80 [2.79]) and control cohort (1.26 [2.35]). In matched analyses, the overall mean (SD) CCI score was highest among the HS cohort (1.95 [2.96]), followed by the psoriasis cohort (1.47 [2.43]; P < .001) and control cohort (0.95 [1.99]; P < .001) patients. A total of 516 patients with HS (13.5%) had an overall mean CCI score of 5 or greater. Mean CCI score was highest for patients with HS across all sex, race, and age groups. The most common comorbidities among patients with HS were chronic pulmonary disease (1540 [40.3%]), diabetes with chronic complications (365 [9.6%]), diabetes without chronic complications (927 [24.3%]), and mild liver disease (455 [11.9%]). Patients with HS with a CCI score of 5 or greater had 4.97 (95% CI, 1.49-16.63) times the adjusted risk of 5-year mortality compared with patients with HS with a CCI score of zero.
Conclusions And Relevance:
Patients with HS have a higher overall comorbidity burden compared with patients with psoriasis and a control group. A significant proportion of patients with HS have CCI scores of 5 or greater, which are associated with increased mortality. This degree of comorbidity burden may warrant multidisciplinary implementation of routine screening measures.
More Related Videos
Related Concept Videos
Comparing Copy Number Variations and SNPs
Copy number variations or CNVs are the structural variations that cover more than 1kb of DNA sequence. The single nucleotide polymorphism (SNP), on the other hand, is a single nucleotide change or a point mutation that is found in more than 1%...
Comparing the Survival Analysis of Two or More Groups
Comparing Experimental Results: Student's t-Test
Comparative Excretory Systems
Comparing Mitochondrial, Chloroplast, and Prokaryotic Genomes
Comparing Intermolecular Forces: Melting Point, Boiling Point, and Miscibility
Temporary attractive forces like dispersion are present in all molecules, whether they are polar or nonpolar. They...

